Abhinav A. Shukla, serving as the Chief Technical Officer for Shattuck Labs, Inc. (NASDAQ: STTK), completed a transaction involving the sale of 410 shares of the company's common stock on July 2, 2026. The total value of this sale was recorded at $2,874. The shares were divested at a weighted average price of $7.01, with specific individual transactions ranging from $7.000 to $7.030 per share. This divestment was carried out in accordance with a Rule 10b5-1 trading plan that was established on February 2, 2026. The primary purpose of this plan is to secure funding for the exercise price and the estimated tax withholding related to option exercises.
This sale activity takes place against a backdrop where Shattuck Labs stock is trading at $7.26, a level close to its 52-week high of $8.33. The stock has experienced an extraordinary 840% gain over the past year. Despite this significant upward trajectory, analysis from InvestingPro suggests that the stock currently appears overvalued relative to its Fair Value, positioning it among companies on the Most Overvalued list.
In conjunction with the sale, Mr. Shukla acquired 410 shares of common stock on July 2, 2026, upon the exercise of stock options at an exercise price of $3.57 per share. Furthermore, on July 6, 2026, he acquired an additional 12,153 shares through the exercise of stock options, also at an exercise price of $3.57 per share. The aggregate value of shares acquired through these exercises amounted to $44,849. These options are part of a larger grant that represents the right to purchase 52,200 shares. The vesting schedule for this grant extends through January 25, 2027, and is contingent upon Mr. Shukla's continued service to the company.
Following these transactions, Mr. Shukla directly holds 98,533 shares of Shattuck Labs common stock and retains 14,140 unexercised stock options. Shattuck Labs has also announced the pricing of a public offering, expecting to raise approximately $75 million in gross proceeds. This offering includes 10,879,376 shares of common stock priced at $4.00 per share and pre-funded warrants for up to 7,870,624 shares. The company has also reported receiving notices to exercise approximately 50.6 million common stock warrants, which is anticipated to generate gross proceeds of about $54.9 million.
Additionally, Shattuck Labs shared positive results from a Phase 1 clinical trial of SL-325, a DR3 blocking antibody candidate. The trial noted a low immunogenicity profile and involved 72 healthy volunteers across various dose cohorts. Recent developments also include the company’s commencement of a public offering of common stock or pre-funded warrants, with an option for underwriters to purchase an additional 15% of shares. These moves indicate Shattuck Labs’ strategic efforts to bolster its financial position and advance its clinical programs.